{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T07:13:53Z","timestamp":1795158833708,"version":"4.10.3"},"reference-count":103,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1,5]]},"abstract":"<jats:p>The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing at an alarming rate. Elevated liver enzymes are a primary reason to refer patients for further testing. However, liver enzymes within the normal range do not exclude the presence of MASLD. We examined the prevalence of MASLD in a middle-aged population with overweight and normal liver enzymes. In addition, we examined the accuracy of 4 sets of noninvasive proxies for MASLD.<\/jats:p>\n          <jats:p>We included 1017 participants from the Netherlands epidemiology of obesity cohort study with body mass index \u226525\u2009kg\/m<jats:sup>2<\/jats:sup> and liver enzymes (asparate aminotransferase, alanine aminotransferase, gamma-glutamyltranspeptidase) within normal range. The diagnostic accuracy of biomarker scores (fatty liver index, liver fat score [LFS], STEATO-ELSA, and hepatic steatosis index) was determined against elevated hepatic triglyceride content measured by <jats:sup>1<\/jats:sup>proton magnetic resonance spectroscopy.<\/jats:p>\n          <jats:p>Participants (mean age 56 years, 49% women), had a median body mass index of 29.6\u2009kg\/m<jats:sup>2<\/jats:sup> and a median hepatic triglyceride content of 4.4%. MASLD was present in 42% of participants and was more common in men than women, with respectively 47% and 36% being affected. The LFS showed the highest accuracy with an area under the curve of 0.72. We identified metabolic syndrome as the prime predictor for MASLD with an odds ratio of 2.95 (95% confidence interval 2.20\u20133.98).<\/jats:p>\n          <jats:p>The prevalence of MASLD in middle-aged men and women with overweight and liver enzymes within the normal range is over 40%. LFS showed the highest accuracy to detect MASLD, but, overall, biomarker scores performed relatively poor. The presence of metabolic syndrome was the prime predictor of MASLD.<\/jats:p>","DOI":"10.1097\/md.0000000000034934","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T07:03:31Z","timestamp":1704870211000},"page":"e34934","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":38,"title":["Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-3715","authenticated-orcid":false,"given":"K.C.","family":"van Son","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands"},{"name":"Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.","family":"te Nijenhuis-Noort","sequence":"additional","affiliation":[{"name":"Department of Dietetics, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Boone","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.O.","family":"Mook-Kanamori","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Holleboom","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.R.","family":"Roos","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.J.","family":"Lamb","sequence":"additional","affiliation":[{"name":"Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Alblas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Coenraad","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.R.","family":"Rosendaal","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"de Mutsert","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Tushuizen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature.","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1530\/EJE-20-0065","article-title":"Non-alcoholic fatty liver disease: a multidisciplinary approach towards a cardiometabolic liver disease.","volume":"183","author":"Ruissen","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.","volume":"64","year":"2016","journal-title":"J Hepatol"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic fatty liver disease: pathogenesis and disease spectrum.","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu Rev Pathol"},{"issue":"2 Suppl 1","key":"R8-20250503","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1002\/hep.20973","article-title":"Nonalcoholic fatty liver disease: from steatosis to cirrhosis.","volume":"43","author":"Farrell","year":"2006","journal-title":"Hepatology"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease.","volume":"13","author":"Arab","year":"2018","journal-title":"Annu Rev Pathol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies.","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1136\/flgastro-2013-100404","article-title":"Non-alcoholic fatty liver disease: a practical approach to treatment.","volume":"5","author":"Dyson","year":"2014","journal-title":"Frontline Gastroenterol"},{"key":"R12-20250503","first-page":"433","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition.","volume":"109","author":"Grundy","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jhep.2012.07.028","article-title":"Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study.","volume":"57","author":"Koehler","year":"2012","journal-title":"J Hepatol"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4321\/S1130-01082013000700006","article-title":"Pathogenesis, diagnosis and treatment of non-alcoholic fatty liver disease.","volume":"105","author":"Mart\u00edn-Dom\u00ednguez","year":"2013","journal-title":"Rev Esp Enferm Dig"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis.","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"R18-20250503","first-page":"721","article-title":"High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients.","volume":"15","author":"Arab","year":"2016","journal-title":"Ann Hepatol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/postgradmedj-2013-201620rep","article-title":"Republished: non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.","volume":"90","author":"Dyson","year":"2014","journal-title":"Postgrad Med J"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis.","volume":"20","author":"Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4103\/1319-3767.61244","article-title":"Liver biopsy for histological assessment: the case against.","volume":"16","author":"Sanai","year":"2010","journal-title":"Saudi J Gastroenterol"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","article-title":"Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.","volume":"288","author":"Szczepaniak","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R23-20250503","first-page":"192","article-title":"MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends.","volume":"3","author":"Ligabue","year":"2013","journal-title":"Quant Imaging Med Surg"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/jmri.27703","article-title":"Assessment of imaging modalities against liver biopsy in nonalcoholic fatty liver disease: the Amsterdam NAFLD-NASH cohort.","volume":"54","author":"Troelstra","year":"2021","journal-title":"J Magn Reson Imaging"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fphar.2016.00159","article-title":"Non-invasive markers of liver fibrosis: adjuncts or alternatives to liver biopsy?","volume":"7","author":"Chin","year":"2016","journal-title":"Front Pharmacol"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12876-020-1165-z","article-title":"Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis.","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2036.2008.03896.x","article-title":"Metabolic and histological features of non-alcoholic fatty liver disease patients with different serum alanine aminotransferase levels.","volume":"29","author":"Wong","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1053\/j.gastro.2009.06.005","article-title":"Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.","volume":"137","author":"Kotronen","year":"2009","journal-title":"Gastroenterology"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MCG.0000000000001007","article-title":"Prediction of liver steatosis applying a new score in subjects from the Brazilian longitudinal study of adult health.","volume":"54","author":"Perazzo","year":"2020","journal-title":"J Clin Gastroenterol"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10654-013-9801-3","article-title":"The Netherlands Epidemiology of Obesity (NEO) study: study design and data collection.","volume":"28","author":"de Mutsert","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"R34-20250503","first-page":"240","article-title":"Het Nederlandse Referentielaboratorium voor Enzymen.","volume":"35","author":"Franck","year":"2010","journal-title":"Ned Tijdschr Klin Chem"},{"key":"R35-20250503","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/nu9080800","article-title":"Dietary composition independent of weight loss in the management of non-alcoholic fatty liver disease.","volume":"9","author":"Eslamparast","year":"2017","journal-title":"Nutrients"},{"key":"R36-20250503","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3109\/07853890.2010.518623","article-title":"Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.","volume":"43","author":"Musso","year":"2011","journal-title":"Ann Med"},{"key":"R37-20250503","doi-asserted-by":"crossref","first-page":"CCR735","DOI":"10.12659\/MSM.883601","article-title":"The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease.","volume":"18","author":"Cicho\u017c-Lach","year":"2012","journal-title":"Med Sci Monit"},{"key":"R38-20250503","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4254\/wjh.v7.i9.1192","article-title":"Composite prognostic models across the non-alcoholic fatty liver disease spectrum: clinical application in developing countries.","volume":"7","author":"L\u00fcckhoff","year":"2015","journal-title":"World J Hepatol"},{"key":"R39-20250503","doi-asserted-by":"crossref","first-page":"17985","DOI":"10.3748\/wjg.v20.i47.17985","article-title":"Ultrasound hepatic\/renal ratio and hepatic attenuation rate for quantifying liver fat content.","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R40-20250503","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"key":"R41-20250503","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2036.2010.04556.x","article-title":"Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.","volume":"33","author":"Dowman","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R42-20250503","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis.","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"R43-20250503","doi-asserted-by":"crossref","first-page":"e107584","DOI":"10.1371\/journal.pone.0107584","article-title":"Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores.","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"R44-20250503","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J Gastroenterol"},{"key":"R45-20250503","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jhep.2018.10.033","article-title":"Non-alcoholic fatty liver disease - A global public health perspective.","volume":"70","author":"Younossi","year":"2019","journal-title":"J Hepatol"},{"key":"R46-20250503","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/jgh.12665","article-title":"Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).","volume":"29","author":"Otgonsuren","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"R47-20250503","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1213\/ANE.0000000000003698","article-title":"Diagnostic testing and decision-making: beauty is not just in the eye of the beholder.","volume":"127","author":"Vetter","year":"2018","journal-title":"Anesth Analg"},{"key":"R48-20250503","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/apt.12963","article-title":"Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.","volume":"40","author":"Fedchuk","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"R49-20250503","doi-asserted-by":"crossref","first-page":"e94059","DOI":"10.1371\/journal.pone.0094059","article-title":"Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance.","volume":"9","author":"Kahl","year":"2014","journal-title":"PLoS One"},{"key":"R50-20250503","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/gut.2007.146019","article-title":"Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.","volume":"57","author":"Harrison","year":"2008","journal-title":"Gut"},{"key":"R51-20250503","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-14-0112","article-title":"External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals.","volume":"171","author":"Cuthbertson","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"R52-20250503","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1053\/j.gastro.2013.06.057","article-title":"Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.","volume":"145","author":"Angulo","year":"2013","journal-title":"Gastroenterology"},{"key":"R53-20250503","doi-asserted-by":"crossref","first-page":"16494","DOI":"10.1038\/srep16494","article-title":"ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population.","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"R54-20250503","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk.","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"R55-20250503","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-9-5","article-title":"Measuring agreement of administrative data with chart data using prevalence unadjusted and adjusted kappa.","volume":"9","author":"Chen","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"R56-20250503","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0016-5085(00)70364-7","article-title":"Liver fibrosis in overweight patients.","volume":"118","author":"Ratziu","year":"2000","journal-title":"Gastroenterology"},{"key":"R57-20250503","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/hep.20207","article-title":"Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index.","volume":"39","author":"Sud","year":"2004","journal-title":"Hepatology"},{"key":"R58-20250503","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1478-3231.2007.01614.x","article-title":"Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis.","volume":"28","author":"Miyaaki","year":"2008","journal-title":"Liver Int"},{"key":"R59-20250503","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1046\/j.1365-2893.1997.00141.x","article-title":"Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus METAVIR and CLINIVIR Cooperative Study Groups.","volume":"4","author":"Poynard","year":"1997","journal-title":"J Viral Hepat"},{"key":"R60-20250503","first-page":"477","article-title":"APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD\/NASH.","volume":"101","author":"Kruger","year":"2011","journal-title":"S Afr Med J"},{"key":"R61-20250503","doi-asserted-by":"crossref","first-page":"e14228","DOI":"10.5812\/hepatmon.14228","article-title":"Non-invasive histologic markers of liver disease in patients with chronic hepatitis B.","volume":"14","author":"Shoaei","year":"2014","journal-title":"Hepat Mon"},{"key":"R62-20250503","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection comparison with liver biopsy and fibrotest.","volume":"46","author":"Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"key":"R63-20250503","first-page":"77","article-title":"Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level.","volume":"60","author":"Ohta","year":"2006","journal-title":"Acta Med Okayama"},{"key":"R64-20250503","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hep.20935","article-title":"A novel panel of blood markers to assess the degree of liver fibrosis.","volume":"42","author":"Cal\u00e8s","year":"2005","journal-title":"Hepatology"},{"key":"R65-20250503","doi-asserted-by":"crossref","first-page":"e58360","DOI":"10.1371\/journal.pone.0058360","article-title":"NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD.","volume":"8","author":"Demir","year":"2013","journal-title":"PLoS One"},{"key":"R66-20250503","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/hep.20772","article-title":"Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort.","volume":"42","author":"Lok","year":"2005","journal-title":"Hepatology"},{"key":"R67-20250503","doi-asserted-by":"crossref","first-page":"e7041","DOI":"10.1097\/MD.0000000000007041","article-title":"Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects.","volume":"96","author":"Zhang","year":"2017","journal-title":"Medicine (Baltim)"},{"key":"R68-20250503","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3350\/kjhep.2011.17.1.19","article-title":"Development and validation of a simple index system to predict nonalcoholic fatty liver disease.","volume":"17","author":"Park","year":"2011","journal-title":"Korean J Hepatol"},{"key":"R69-20250503","doi-asserted-by":"crossref","first-page":"e0272","DOI":"10.1097\/MD.0000000000010272","article-title":"A novel index including SNPs for the screening of nonalcoholic fatty liver disease among elder Chinese: a population-based study.","volume":"97","author":"Yang","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"R70-20250503","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1373\/clinchem.2005.048389","article-title":"Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection.","volume":"51","author":"Adams","year":"2005","journal-title":"Clin Chem"},{"key":"R71-20250503","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/hep.22241","article-title":"A clinical scoring system for predicting nonalcoholic steatohepatitis in morbidly obese patients.","volume":"47","author":"Campos","year":"2008","journal-title":"Hepatology"},{"key":"R72-20250503","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1572-0241.2006.01041.x","article-title":"Nonalcoholic fatty liver disease in severely obese subjects.","volume":"102","author":"Gholam","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R73-20250503","doi-asserted-by":"crossref","first-page":"e23077","DOI":"10.1371\/journal.pone.0023077","article-title":"A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B.","volume":"6","author":"Seto","year":"2011","journal-title":"PLoS One"},{"key":"R74-20250503","first-page":"548","article-title":"A new scoring system for prediction of fibrosis in chronic hepatitis C.","volume":"11","author":"Bota","year":"2011","journal-title":"Hepat Mon"},{"key":"R75-20250503","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jhep.2012.04.025","article-title":"Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.","volume":"57","author":"Poynard","year":"2012","journal-title":"J Hepatol"},{"key":"R76-20250503","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1572-0241.2005.41289.x","article-title":"Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model.","volume":"100","author":"Hui","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R77-20250503","first-page":"1302","article-title":"Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.","volume":"92","author":"Bonacini","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"R78-20250503","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3748\/wjg.v18.i8.746","article-title":"Routine blood tests to predict liver fibrosis in chronic hepatitis C.","volume":"18","author":"Hsieh","year":"2012","journal-title":"World J Gastroenterol"},{"key":"R79-20250503","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/00365520510015674","article-title":"Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers.","volume":"40","author":"Islam","year":"2005","journal-title":"Scand J Gastroenterol"},{"key":"R80-20250503","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-230X-11-44","article-title":"A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI).","volume":"11","author":"Ahmad","year":"2011","journal-title":"BMC Gastroenterol"},{"key":"R81-20250503","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2004.08.052","article-title":"Serum markers detect the presence of liver fibrosis: a cohort study.","volume":"127","author":"Rosenberg","year":"2004","journal-title":"Gastroenterology"},{"key":"R82-20250503","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/hep.24515","article-title":"Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?","volume":"54","author":"Guha","year":"2011","journal-title":"Hepatology"},{"key":"R83-20250503","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-230X-6-6","article-title":"Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.","volume":"6","author":"Ratziu","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"R84-20250503","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jhep.2005.02.025","article-title":"Prediction of hepatic fibrosis in HIV\/HCV co-infected patients using serum fibrosis markers: the SHASTA index.","volume":"43","author":"Kelleher","year":"2005","journal-title":"J Hepatol"},{"key":"R85-20250503","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1476-5926-4-10","article-title":"The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis.","volume":"4","author":"Poynard","year":"2005","journal-title":"Comp Hepatol"},{"key":"R86-20250503","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/MEG.0b013e32830dfcb3","article-title":"King\u2019s Score: an accurate marker of cirrhosis in chronic hepatitis C.","volume":"21","author":"Cross","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R87-20250503","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s11695-010-0204-1","article-title":"A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis.","volume":"21","author":"Younossi","year":"2011","journal-title":"Obes Surg"},{"key":"R88-20250503","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s11695-010-0118-y","article-title":"A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients.","volume":"20","author":"Ulitsky","year":"2010","journal-title":"Obes Surg"},{"key":"R89-20250503","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1111\/j.1478-3231.2008.01784.x","article-title":"Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis.","volume":"28","author":"Fung","year":"2008","journal-title":"Liver Int"},{"key":"R90-20250503","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/hep.21520","article-title":"FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C.","volume":"45","author":"Koda","year":"2007","journal-title":"Hepatology"},{"key":"R91-20250503","doi-asserted-by":"crossref","first-page":"e0167776","DOI":"10.1371\/journal.pone.0167776","article-title":"Development of serum marker models to increase diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease: the new LINKI Algorithm compared with Established Algorithms.","volume":"11","author":"Lykiardopoulos","year":"2016","journal-title":"PLoS One"},{"key":"R92-20250503","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cca.2017.09.020","article-title":"NAFL screening score: a basic score identifying ultrasound-diagnosed non-alcoholic fatty liver.","volume":"475","author":"Zhou","year":"2017","journal-title":"Clin Chim Acta"},{"key":"R93-20250503","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/jgh.13235","article-title":"The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease.","volume":"31","author":"Goh","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"key":"R94-20250503","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.","author":"Hagstr\u00f6m","year":"2023","journal-title":"J Hepatol"},{"key":"R95-20250503","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/hep.30626","article-title":"Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps.","volume":"70","author":"Lonardo","year":"2019","journal-title":"Hepatology"},{"key":"R97-20250503","doi-asserted-by":"crossref","first-page":"9488","DOI":"10.3748\/wjg.v22.i43.9488","article-title":"Nonalcoholic fatty liver disease - A multisystem disease?","volume":"22","author":"Mikolasevic","year":"2016","journal-title":"World J Gastroenterol"},{"key":"R98-20250503","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2017.09.021","article-title":"Hypertension, diabetes, atherosclerosis and NASH: cause or consequence?","volume":"68","author":"Lonardo","year":"2018","journal-title":"J Hepatol"},{"key":"R99-20250503","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2013-1519","article-title":"Resolution of fatty liver and risk of incident diabetes.","volume":"98","author":"Sung","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R100-20250503","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.01.009","article-title":"Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension.","volume":"60","author":"Sung","year":"2014","journal-title":"J Hepatol"},{"key":"R101-20250503","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.2337\/dc15-0140","article-title":"Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes.","volume":"38","author":"Yamazaki","year":"2015","journal-title":"Diabetes Care"},{"key":"R102-20250503","doi-asserted-by":"crossref","first-page":"1032164","DOI":"10.3389\/fendo.2022.1032164","article-title":"Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis.","volume":"13","author":"Houttu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R103-20250503","doi-asserted-by":"crossref","first-page":"716783","DOI":"10.3389\/fnut.2021.716783","article-title":"Dietary interventions in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"8","author":"Houttu","year":"2021","journal-title":"Front Nutr"},{"key":"R104-20250503","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome--a new world-wide definition A Consensus Statement from the International Diabetes Federation.","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"R105-20250503","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease.","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034934","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:23:56Z","timestamp":1746318236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000034934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000034934","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}